LEUKOCARE AG

Company

    • Company type:
      • Research & Development
    • Year founded:
    • 2003
    • Employees (at the site):
    • 21
    • Turnover range:
    • <5m EUR
    • Products/services:
    • LEUKOCARE provides a next-generation formulation technology platform for the protection of proteins like biopharmaceuticals to allow the development of better products. The proprietary Stabilizing and Protecting Solutions (SPS®) technologies are provided to development projects of partners in the pharmaceutical and medical device industry. As different stakeholders have different needs, the SPS® platform is separated into the following three main pillars:

      - improvement of thermal stability
      - protection during sterilization
      - functionalization of medical devices

      LEUKOCARE's SPS® technologies improve stability and quality of biologics like antibodies, vaccines including live viral vectors etc. in dry and liquid formulation and protect proteins in biologically functionalized medical devices like implants, wound dressings, microneedles etc. during sterilization.

    • Core competencies:
    • not available

    • Language skills:
    • English
      German
    • Key Tech / section:
      • Biotechnology: Animal health
      • Biotechnology: Preclinical development
      • Biotechnology: Prophylactic drug development
      • Biotechnology: Therapeutic drug development
      • Medical Technology: Dialysis, apheresis
      • Medical Technology: Immunology
      • Medical Technology: Implants, biomaterials, tissue engineering
    • Industries NACE:
      • 72: Scientific research and development
      • 72.1: Research and experimental development on natural sciences and engineering
      • 72.11: Research and experimental development on biotechnology
    • Certification:
    • LEUKOCARE’s research and development activities are based on its well established quality management system (QM) according to EN ISO 9001 and EN ISO 13485. LEUKOCARE's laboratories have permission for Biosafety Level 2.

    • Sales markets - target industries:
    • not available
    • Sales markets - target countries:
      • Australia
      • Austria
      • Belgium
      • Canada
      • China
      • Denmark
      • Finland
      • France
      • Germany
      • Iceland
      • India
      • Indonesia
      • Ireland
      • Italy
      • Japan
      • Korea, Republic of
      • Luxembourg
      • Netherlands
      • New Zealand
      • Norway
      • Poland
      • Portugal
      • Singapore
      • Spain
      • Sweden
      • United Kingdom
      • United States
    • Cooperation offers:
    • LEUKOCARE provides a next-generation formulation technology platform for the protection of proteins like biopharmaceuticals to allow the development of better products. LEUKOCARE's SPS® technologies improve stability and quality of biologics like antibodies, vaccines including live viral vectors etc. in dry and liquid formulation and protect proteins in biologically functionalized medical devices like implants, wound dressings, microneedles etc. during sterilization. Beyond, LEUKOCARE supports its partners with related services and know how in order to evaluate and to implement the SPS® technologies and formulations in the partnered products: Development of individual SPS® formulations Development of accelerated aging models Development of customized lyophilization protocols Development of spray drying and spray freeze drying processes Coupling of biological compounds to functionalize surfaces Establishment of biological read outs Capabilities to work with biosafety level 2 material
    • Contact person:
    • Simone Knappmann (Mrs.)
      - Sales / marketing

      Dr. med. Roland Derwand (Mr.)
      - Cooperation

      Michael Scholl (Mr.)
      - Management